ArticleEuropean journal of medical research2025
Association of DRD4 promoter-associated methylation with mild cognitive impairment in Han and Uygur populations.
Article in European journal of medical research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Protective effects of gastrodin against bisphenol A-induced dopaminergic dysregulation and cognitive impairment in rats.Naunyn-Schmiedeberg's archives of pharmacology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
Abstract
backgroundMild cognitive impairment (MCI) is a prodromal stage of Alzheimer's disease characterized by subjective cognitive decline and objective evidence of cognitive impairment revealed through neuropsychological examinations. Dopamine receptors play a pivotal role in the modulation of memory and cognitive functions. DRD4 is a dopamine receptor gene enriched in memory-related brain regions, modulates synaptic plasticity, and its promoter methylation status. While DRD4 promoter methylation is implicated in neurodevelopmental disorders, its role in MCI pathogenesis remains uninvestigated across ethnically diverse populations. PURPOSE: Our study focused on the association between DRD4 methylation and MCI in Uygur and Han populations. PATIENTS AND
methods192 age-sex-matched participants (48 Uygur MCI, 48 Uygur controls, 48 Han MCI, 48 Han controls) were recruited from Xinjiang and Zhejiang, China. MCI diagnosis followed DSM-IV criteria with cognitive assessment (MMSE/MoCA). Peripheral blood DNA underwent bisulfite conversion, followed by pyrosequencing of DRD4 promoter CpG sites 1-4 (PyroMark Q24). Group comparisons used independent t-tests with two-way ANOVA for covariate adjustment (age/sex/ethnicity); Pearson/Spearman tests assessed methylation-biomarker correlations. Methylation was measured using bisulfite pyrosequencing.
resultsOur results indicated that MCI-related hypermethylation was detected in the Uygur (CpG1) and Han (CpG1-3) populations, and subgroup analyses by sex in the Uygur population displayed consistent results, while in the Han subgroup, DRD4 hypermethylation was only observed in the male group. Ethnic differences in CpG4 (CpG: cytosine phosphate guanine) in male cases, CpG1 in overall control, and CpG3 in male controls. Regional distinctions were shown between CpG1and CpG4 in the male subgroup. Diverse correlations were observed. CpG1 methylation in the Uygur male control groups, Uygur female case groups, and Han female control groups was significantly correlated with age, Glu, and HDL-C, respectively. CpG2 in Uygur male controls and Uygur female patients showed correlations with Glu and TG levels. CpG3 in Uygur male and Han male controls was significantly correlated with TC and HDL-C levels. CpG4 in Uygur female controls and Han female patients correlated with Glu and age.
conclusionOur findings provide novel insights into DRD4 methylation in Uygur and Han populations.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.